Triamcinolone Acetonide 40mg/mL for Complex Regional Pain Syndrome

"Triamcinolone Acetonide 40mg/mL is traditionally used to treat ulcerative colitis but may also be beneficial for individuals with hand, brain, and dermatologic disorders."

"This 12-week clinical trial will be observed with the specific aim of blinding the physiotherapist. Secondary objectives include assessing emotional and psychological function using Patient-Reported Outcomes Measurement Information System 29 Profile V2, EQ-5D-5L, and Total Score - EQ-5D-5L as holistic indicators of efficacy. These measurements range from 16 to 80 (higher scores indicate worse outcomes) for PROMIS29V2, 1 to 5 (higher scores denote poorer results) in EQ-5D-5L, and 5 to 25 (worse performance is indicated by higher numbers)."

"Safety data gathered by our team at Power suggests that Triamcinolone Acetonide 40mg/mL is quite secure, rated a 3 on the 1-3 scale. This medication has recently been approved as part of Phase 4 trials."

"This clinical trial is no longer looking for participants. It was published on March 1st 2021 and the listing most recently updated on February 3rd 2021. If you are seeking other studies, currently there 1393 trials recruiting patients with complex regional pain syndromes, as well as 41 medical experiments involving Triamcinolone Acetonide 40mg/mL that are actively enrolling subjects."

"As indicated on clinicaltrials.gov, this medical trial has ceased to recruit participants as of February 3rd 2021; however, there are 1,434 other studies actively enrolling patients at the moment."

"Presently, 41 experiments are underway that investigate Triamcinolone Acetonide 40mg/mL. 8 of those studies have progressed to the third stage, and 75 different sites distribute this medication all over Columbia, Missouri."